



Mills, A (2016) The Challenges of Prioritization. Health Systems & Reform, 2 (1). p. 20. ISSN 2328-8604 DOI: https://doi.org/10.1080/23288604.2016.1124173

Downloaded from: http://researchonline.lshtm.ac.uk/4328604/

DOI: 10.1080/23288604.2016.1124173

<u>a · i i i</u>

πт

Usage Guidelines				
Please refer to usage guideline tively contact researchonline@lshtm	÷ / /	archonline.lsht	m.ac.uk/policies	.html or alterna-
Available under license: http://creativecommons.org/licens	Creative es/by-nc/3.0/	Commons	Attribution	Non-commercial





Health Systems & Reform

ISSN: 2328-8604 (Print) 2328-8620 (Online) Journal homepage: http://www.tandfonline.com/loi/khsr20

The Challenges of Prioritization

Anne Mills

To cite this article: Anne Mills (2016) The Challenges of Prioritization, Health Systems & Reform, 2:1, 20-20, DOI: 10.1080/23288604.2016.1124173

To link to this article: http://dx.doi.org/10.1080/23288604.2016.1124173

6

© 2015 The Author(s). Published with license by Taylor & Francis Group, LLC© Anne Mills



Published online: 21 Jan 2016.



🕼 Submit your article to this journal 🗗

Article views:	604
Article views:	604



View related articles 🗹




View Crossmark data 🗹



Citing articles: 2 View citing articles

Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=khsr20

Commentary



Anne Mills*

London School of Hygiene & Tropical Medicine, London, UK


Keywords: cost-effectiveness analysis, disease control, economic analysis, health system surveillance, priority setting

© Anne Mills

Received 15 November 2015; revised 18 November 2015; accepted 20 November 2015.

*Correspondence to: Anne Mills; Email: anne.mills@lshtm.ac.uk

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons. org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.



In addition, economic tools such as cost-effectiveness and cost-benefit analysis have their limitations when it comes to encompassing the range of types of decisions needing to be evaluated to guide resource allocation. A particular concern of mine is that the analytical method should not excessively drive the nature of the issues being prioritized for resources. Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not well researched or understood. In addition, benefits of policy action are not necessarily confined to health, with broader effects both on general well-being and across different sectors. Both the evidence base of the link between inputs and outputs and the conceptualization of relevant costs and benefits present far more challenges to analysts.

Health decision makers need to prioritize not just a benefits package of specific interventions but also broader public health packages and public health systems—such as surveillance—that cannot easily be evaluated within standard priority-setting approaches. Greater attention needs to be paid to how best to do this, in order to avoid further accentuating the medicalization of our health systems.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

No potential conflicts of interest were disclosed.

